Observational Aranesp® Survey to Investigate the Q3W Schedule (OASIS): A prospective observational study of treatment of chemotherapy-induced anaemia with every 3 weeks darbepoetin alfa

Supportive Care in Cancer

Volumn 17, Issue 2, 2009, Pages 211-215

  Pat, K ^a   Anrys, B ^a   Verhulst, D ^b   Van Aelst, F ^c   Van Eygen, K ^d   Galdermans, D ^e   Verhoeven, D ^f   Polus, M ^g   Segers, K ^h   Derde, M P ⁱ   Wauters, I ^a   Vansteenkiste, J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Cliniques de l'Europe   (Belgium)

^c Heilig Hart Ziekenhuis   (Belgium)

^d AZ GROENINGE   (Belgium)

^e ZNA Middelheim   (Belgium)

^f Algemeen Ziekenhuis Klina   (Belgium)

^g UNIVERSITY OF LIÈGE   (Belgium)

^h Amgen NV   (Belgium)

ⁱ Veeda Clinical Research   (United Kingdom)

Author keywords

Chemotherapy induced anaemia; Erythropoietin; Extended dosing interval; Implementation study; Prospective study

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLATINUM COMPLEX; ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ERUPTION; ERYTHROCYTE TRANSFUSION; FEMALE; HEADACHE; HEALTH SURVEY; HEART INFARCTION; HEMATOLOGIC MALIGNANCY; HUMAN; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SOLID TUMOR; SUPERFICIAL VEIN THROMBOSIS; TREATMENT OUTCOME; VEIN THROMBOSIS; BELGIUM; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; OBSERVATION; PRACTICE GUIDELINE; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; BELGIUM; ERYTHROPOIETIN; FEMALE; GUIDELINE ADHERENCE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; OBSERVATION; PROSPECTIVE STUDIES;

EID: 58149084841     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-008-0517-y     Document Type: Article

References (8)

1. J Bohlius S Langensiepen G Schwarzer J Seidenfeld M Piper C Bennett 2005 Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis J Natl Cancer Inst 97 489 498
2. J Bohlius J Wilson J Seidenfeld M Piper G Schwarzer J Sandercock 2006 Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients J Natl Cancer Inst 98 708 714
3. C Bokemeyer MS Aapro A Courdi J Foubert H Link A Osterborg 2004 EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer Eur J Cancer 40 2201 2216
4. C Bokemeyer MS Aapro A Courdi J Foubert H Link A Osterborg 2007 EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update Eur J Cancer 43 258 270
5. JL Canon J Vansteenkiste G Bodoky MV Mateos L Bastit I Ferreira 2006 Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia J Natl Cancer Inst 98 273 284
6. J Glaspy D Henry R Patel S Tchekmedyian S Applebaum D Berdeaux 2005 Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa Eur J Cancer 41 1140 1149
7. J Vansteenkiste R Pirker B Massuti F Barata A Font M Fiegl 2002 Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy J Natl Cancer Inst 94 1211 1220
8. J Vansteenkiste I Wauters 2007 Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals Expert Rev Anticancer Ther 7 1347 1355